Skip to content

Australasian Psychiatry

ISSN 1039-8562

5 papers in the library · 3 citations · publishing 2018-2026

Papers

Sort Most recent Most cited

The risk of psychosis associated with cannabis use by people with attention-deficit hyperactivity disorder: A systematic review

Australasian Psychiatry March 31, 2026 Shuichi Suetani, Faraz Honarparvar, Peter Muller et al.

Background Given that both attention-deficit hyperactivity disorder (ADHD) and cannabis use are known independent risk factors for psychosis, people with ADHD who consume cannabis may be especially vulnerable. The main objective of the current study was to explore the links between ADHD, cannabis use and psychosis outcomes. Methods A systematic review was conducted to examine the risk of...

The clinical use of dream content in modern psychiatry

Australasian Psychiatry January 2, 2025 David Plevin, Virginia Munro 1 citation

ObjectiveThough there is a rich psychoanalytic tradition investigating the content and phenomenology of dreams, the clinical use of this has fallen into widespread disuse. We have undertaken a narrative review of the clinical significance and utility of dream content.FindingsDream content may have useful clinical and prognostic value in a number of neurological and psychiatric conditions,...

What clinicians need to know about intranasal esketamine for treatment-resistant depression?

Australasian Psychiatry November 14, 2023 Judith D. Hope, David Copolov, John Tiller et al.

Objective To review the usefulness of esketamine for treatment-resistant depression. Method Pivotal trials of intranasal esketamine in treatment-resistant depression were synthesized as a narrative review. Results Esketamine is postulated to act through antagonism of N-methyl-D-aspartate (NMDA) glutamate receptors, but opioidergic effects may also be involved. Unlike intravenous ketamine,...

Intranasal esketamine for depression: Not so special K

Australasian Psychiatry August 1, 2022 Stephen Rosenman 2 citations

Background Intranasal esketamine has been recently approved for the treatment of resistant depression. It is the only form of ketamine approved. The formulation costs around $600 per dose while plain injected ketamine, on which most research has been done, costs less than $20 per dose. Research shows that intranasal esketamine is less effective and has more unwanted effects than injected...

The trip of a lifetime: hallucinogen persisting perceptual disorder

Australasian Psychiatry February 1, 2018 Lauren Anderson, Hannah Lake, Mark Walterfang

Objectives: The differential diagnosis of psychotic symptoms is broad and extends beyond primary psychotic and affective disorders. We aim to illustrate that the chronology and phenomenological nature of hallucinatory symptoms may provide clues towards alternative diagnoses, such as hallucinogen persisting perceptual disorder (HPPD). We describe the resurgence of visual pseudo-hallucinations in...